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OBJECTIVES The aim of the present study was to determine if myocytes can die by apoptosis in fibrillating
and dilated human atria.
BACKGROUND The cellular remodeling that occurs during atrial fibrillation (AF) may reflect a degree of
dedifferentiation of the atrial myocardium, a process that may be reversible.
METHODS We examined human right atrial myocardium specimens (n 5 50) for the presence of
apoptotic myocytes. We used immunohistochemical and Western blotting analysis to
examine the expression of a final effector of programmed cell death, caspase-3 (CASP-3) and
of regulatory proteins from the BCL-2 family.
RESULTS Sections from atria in AF contained a high percentage of large myocytes with a disrupted
sarcomeric apparatus replaced by glycogen granules (64.4 6 6.3% vs. 12.2 6 5.8%). These
abnormal myocytes, which also predominated in atria from hearts with decreased left
ventricular ejection fraction (42.3 6 10.1%), contained large nuclei, most of which were
TUNEL positive, indicating a degree of DNA breakage. None of these abnormal myocytes
expressed the proliferative antigen Ki-67. A small percentage of the enlarged nuclei (4.2 6
0.8%) contained condensed chromatin and were strongly TUNEL positive. Both the pro- and
activated forms of CASP-3 were detected in diseased myocardial samples, which also showed
stronger CASP-3 expression than controls. Expression of the antiapoptotic BCL-2 protein
was decreased in diseased atria, whereas that of the proapoptotic BAX protein remained
unchanged.
CONCLUSIONS In fibrillating and dilated atria, apoptotic death of myocytes with myolysis contributes to
cellular remodeling, which may not be entirely reversible. (J Am Coll Cardiol 1999;34:
1577–86) © 1999 by the American College of Cardiology
Atrial fibrillation (AF) is the most frequent sustained
cardiac arrhythmia and causes serious deleterious effects
such as impairment of cardiac function or thromboembolic
events (1). This arrhythmia is due to circuits of micro-
reentry of electrical impulses in the atrial wall, a process
referred to as the multiple-wavelets mechanism (2). The
incidence of wavelets that can coexist is determined by both
the mass and the electrical vulnerability of the atrial myo-
cardium, explaining why AF is often observed in clinical
situations associated with atrial enlargement and shortening
of the atrial refractory period (3,4). The other major
characteristic of AF is its tendency to become sustained,
suggesting that AF induces a vicious circle leading to the
increase in its arrhythmogenic substrate (4).
Distinct cellular alterations occur in AF that may also
contribute to its perpetuation. In human atrial biopsies or in
animal models of AF, a number of myocytes lose their
sarcomeric apparatus, which is replaced by accumulation of
glycogen granules (5–9). Because these abnormal myocytes
reexpress some fetal proteins, it has been proposed that they
are dedifferentiated, reflecting a certain degree of adaptation
of the atrial myocardium to changes in its working condi-
tions, a process that may be reversible (9). It is also
conceivable that as the result of the persistence of patho-
genic factors such as increased pressure load or high fre-
quency of beating, some of the myocytes with structural
alterations could activate a programmed cell death (PCD)
pathway.
Programmed cell death is an active cell suicide mecha-
nism culminating in characteristic features commonly
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known as apoptosis. During this process, caspases, which
are highly specific cysteine proteases, function in both cell
disassembly and in initiating this disassembly in response to
proapoptotic signals by cleaving a discrete set of proteins
such as ICAD/CAD, gelsolin or proteins involved in DNA
repair such as Poly (ADP ribose) polymerase (10,11). The
caspases are all expressed as proenzymes that contain three
domains: an NH2-terminal domain, a large and a small
subunit. Activation involves proteolytic processing between
domains, followed by association of the large and small
subunits to form a functional heterodimer. The Caspase-3/
CPP32 (CASP-3) is one of the major caspases involved in
apoptosis (11). BCL-2 is the founding member of a
growing family of proteins that either protect against cell
death such as BCL-2 or that promote apoptosis such as
BAX (12). The data available to date indicate that BCL-2
family proteins may dictate whether effector caspases be-
come active or remain quiescent after exposure of cells to
apoptotic stimuli (13). Both caspases and BCL-2 family
proteins are involved in the apoptosis of cardiac myocytes,
which occurs in various cardiopathies (14–17).
The aim of the present study was to examine if atrial
myocytes can undergo an apoptotic-like death process in
chronic AF or in clinical settings associated with a high
incidence of this arrhythmia.
METHODS
Cardiac specimens. With approval from our Ethics Com-
mittee, specimens of the right atrial appendage were ob-
tained from 50 patients (31 to 86 years old) undergoing
heart surgery for coronary artery disease, valve disease or
congenital heart defects (Table 1). Patients with chronic AF
had left and right atrial dilation (.45 mm), most often
associated with increased systolic pulmonary pressure
(.35 mm Hg) indicating longstanding valve disease (18).
Specimens of the right atrial appendage were fixed imme-
diately after excision and maintained in 10% buffered
formalin overnight or fixed 3 h in Bouin solution and
embedded in paraffin or frozen in liquid nitrogen (L2N) or
isopentane.
Histological analysis. Tissue sections were deparaffinized,
transferred to xylene and rehydrated in decreasing concen-
trations of alcohol. Then slides were stained with hematein,
eosin, orcein, Masson’s trichrome or periodic acid schiff.
Myocyte diameter was determined by measuring the short
axis of 100 randomly chosen cells per field. To quantify the
amount and the percentage of myocytes with myolysis, two
sections per atrial samples were analyzed, and at least 400
cells per section were analyzed. Cells were scored by
morphometry as severely myolytic if .25% of the sarcomere
was absent.
Immunohistochemistry. Cryo-sections (5 mm) were incu-
bated in phosphate-buffered saline (PBS) containing 5%
BSA, followed by incubation with mouse anti-rabbit sarco-
meric a-actinin antibody (1/400; Sigma Aldrich, St. Louis,
Missouri), then incubated with goat biotinylated anti-
mouse IgG secondary antibody (1/30; Vector Laboratories,
Paris, France) and with streptavidin-Texas red or fluores-
cein (1/30; Amersham). Some observations were carried out
with an MRC-1024 (Bio-Rad, UK) confocal scanning laser
with microscope (Nikon Optiphot Fluorescence) using
Lasersharp (Bio-Rad).
For expression and localization of CASP-3, BCL-2 and
BAX proteins, deparaffinized sections were either used
directly or subjected to microwave oven antigen retrieval
treatment (19,20). Tissue sections were immunostained
with a rabbit anti-CASP-3, anti-BCL-2 or anti-BAX
antiserum. The immunoreactions were visualized with a
diaminobenzidine (DAB)-based colorimetric method, as
previously described (20). Slides were lightly counterstained
with hematoxylin and permanently mounted with De-Pe-X
(Fluka, Buchs, Germany) before being analyzed and photo-
graphed with an Olympus BH-2 microscope connected to a
camera. The specificity of the staining was confirmed by
using preimmune serum and/or by preabsorbing the anti-
serum with specific peptide or recombinant protein before
performing immunostaining.
Western blot. Protein lysates were prepared, normalized
for total protein content (200 or 100 mg per lane) and
analyzed by 12.5% or 10% SDS-PAGE, followed by
electro-transfer to polyvinylidene difluoride membranes
(Bio-Rad). Immunodection was performed using anti-
CASP-3 (19), anti-BCL-2, anti-BAX (20) antitubulin or
anti-a-actinin sarcomeric monoclonal (Sigma, St. Louis,
MO) antibodies followed by horseradish peroxydase
(HRPase)-conjugated secondary antibody (Amersham Life
Sciences). Detection was performed using enhanced chemi-
luminescence detection method (ECL1; Amersham Life
Science). Densitometric analysis was performed using Gel
analyst system (ICONIX).
Staining of Ki-67 antigen. The staining of Ki-67 antigen
was performed on paraffin-embedded sections, using the
MIB-1 monoclonal antibody (1/1,000 dilution; DakoA/S,
Copenhagen, Denmark). Detection was accomplished using
streptavidin biotinylated horseradish peroxydase method
(Dako). DAB tetrahydrochloride 0.06% in PBS containing
Abbreviations and Acronyms
AF 5 atrial fibrillation
CASP-3 5 caspase 3




LLVEF 5 low left ventricular ejection fraction
PBS 5 phosphate-buffered saline
PCD 5 programmed cell death
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1 Male 78 AF (1 month) AS 32 55 , 25
2 Female 67 AF (10) MR 45 58 50
3 Female 74 AF (12) MS 46 65 , 25
4 Male 69 AF (13) MR 50 44 40
5 Male 54 AF (2) MS 52 63 35
6 Female 66 AF (20) MS 50 63 53
7 Male 69 AF (3) MS 52 56 , 25
8 Female 65 AF (6) AS 50 50 , 25
9 Male 51 AF (7) MS/AI 35 54 , 25
10 Female 73 AF (7) MS 54 65 41
11 Male 86 AF (8) AS 50 50 30
12 Male 34 AF (2) HypoRV 10 70 24
13 Male 69 AF (5) MR 56 50 60
14 Male 77 AF (10) CAD 50 59 , 25
15 Male 71 AF (5) MR 58 48 45
16 Male 64 AF (9) MR 35 70 45
14 Male 77 AF (5) CAD 66 58 35
15 Male 78 Flutter (2) AS 40 39 60
15 Male 31 SR CAD 55 36 , 25
16 Male 63 SR CAD 50 40 , 25
17 Male 55 SR CAD 55 35 , 25
18 Male 59 SR CAD 55 35 , 25
19 Male 53 SR CAD 55 40 , 25
20 Male 54 SR CAD , 20 . 50 . 50
21 Male 59 SR CAD , 20 . 50 . 50
22 Male 44 SR CAD , 20 . 50 . 50
23 Female 74 SR CAD 29 49 , 25
24 Female 38 SR AS/AI 60 29 , 25
25 Female 44 SR CAD 50 30 , 25
26 Male 65 SR CAD 47 30 , 25
27 Male 47 SR CAD 70 30 , 25
28 Male 60 SR CAD 20 30 , 25
29 Female 48 SR CAD 60 31 , 25
30 Male 70 SR CAD 47 35 , 25
31 Male 57 SR CAD 47 37 , 25
32 Male 81 SR AS 50 37 30
33 Female 68 SR CAD 40 38 , 25
34 Male 77 SR CAD 50 38 , 25
35 Male 53 SR MS 50 39 52
36 Female 62 SR CAD 60 39 , 25
37 Female 45 SR MR 48 39 , 25
38 Male 54 SR CAD 60 41 , 25
39 Female 77 SR CAD 45 45 30
40 Male 75 SR AS 45 46 , 25
41 Male 78 SR CAD 60 46 , 25
42 Female 82 SR CAD 60 47 , 25
43 Female 75 SR CAD 30 47 45
44 Male 66 SR AS 35 47 35
45 Male 75 SR AS 58 48 , 25
46 Male 38 SR MR 42 58 65
47 Male 77 SR MR 50 45 45
48 Female 74 SR AS/CAD 50 39 , 25
49 Male 73 SR AS 11 54 32
50 Male 70 SR AS 55 58 , 25
AI 5 aortic insufficiency; AS 5 aortic stenosis; CAD 5 coronary artery disease; EF 5 ejection fraction; HypoRV 5 hypo right ventricule; LA 5 left atrium; MR 5 mitral
regurgitation; MS 5 mitral stenosis; PAP 5 pulmonary artery pressure; SR 5 sinus rhythm.
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0.03% hydrogen peroxyde was used as a chromogen. As
positive control, we used sections from squamous cell
carcinomas.
Nuclear staining with DAPI. Deparaffinized tissue sec-
tions were incubated with the intercalating agent DAPI (49,
6-diamidino-2-phenylindole, 0.3 mg/ml in PBS, 15 min) to
visualize nuclear morphology.
TUNEL assay. Sections were transferred to xylene and
rehydrated in decreasing concentrations of alcohol. Slides
were then incubated (10 min, room temperature) with
10 mg of proteinase K (Sigma-Aldrich, St. Louis, MO) per
milliliter of PBS. Endogenous peroxydase was inactivated
by immunopure peroxydase suppressor for 30 min (Pierce).
Tissue sections permeabilized with 1% Triton X-100 (4°C,
2 min) were stained with an in situ cell detection (POD)
system (Boehringer Mannheim, Mannheim, Germany).
DNA-strand breaks were identified by labeling free 39-OH
termini with dUTP-FITC using the terminal deoxynucleo-
tidyl transferase (Tdt; TUNEL). Incorporated fluorescein
was detected by anti-fluorescein antibody Fab fragment
from sheep conjugated with horseradish peroxydase (POD).
After reaction with the substrate metal-enhanced DAB
(Boehringer Mannheim, Germany), sections were counter-
stained with hematoxylin. Positive controls consisted of
incubating fixed and permeabilized sections with DNase I
(1 mg/ml) (10 min, room temperature). For negative con-
trols, sections were incubated in labeling solution without
Tdt. The percentage of TUNEL 2 positive nuclei was
calculated as followed: 50 randomly chosen fields per section
corresponding to approximately 700 cells were examined at
high magnification (3400).
DNA gel electrophoresis. Fragments of atrial myocar-
dium were crushed in liquid nitrogen, homogenized, fixed
with 70% ethanol and incubated in 40 ml of phosphate-
citrate buffer (pH 7.8). The pellet was resuspended in 0.5 ml
of lysis buffer containing 75 mM NaCl, 0.5% SDS, 10 mM
Tris-HCl, 10 mM EDTA, pH 8.0 and 0.15 mg/ml pro-
teinase K (Sigma-Aldrich) and incubated at 50°C for 3 h.
The lysate was then incubated with 200 mg/ml RNase A
(Sigma-Aldrich) at 37°C for 1 h (25). After extraction with
phenol and chlorophorm, DNA was precipitated with 2 vol
of ethanol and centrifuged; the pellet was washed with 70%
ethanol and resolubilized in an appropriate volume of TE
(10 mM Tris [Ethylenediaminetetraacetate disodium]-
HCl, 1 mM EDTA, pH 8.0). DNA was quantified by
means of spectrophotometry. Equal amounts of each sample
(10 mg) were loaded on 1.5% agarose gels containing
0.5 mg/ml ethidium bromide, alongside 2 mg of molecular
weight DNA marker (123-bp DNA ladder; Sigma-
Aldrich). DNA laddering was visualized under ultraviolet
light.
Statistical analysis. Data on structural cellular changes
were tested for statistical significance by a one-way analysis
of variance for multiple comparison. A p value below 0.05
was considered significant after correction with Fischer post
hoc statistical test. Values are expressed as mean 6 standard
error of the mean.
RESULTS
Marked structural cellular alterations in diseased atria.
Figure 1 shows a typical tissue section of the right atrial
specimen of a patient in sinus rhythm without atrial
dilation. Myocytes of relatively uniform size were regularly
arranged in parallel to their long axis. Muscle bundles were
surrounded by a thin connective tissue with absent-to-
moderate interstitial fibrosis (Fig. 1, A and C). By contrast,
tissue sections from a dilated and chronically fibrillating
atrium exhibited large areas of extensive structural alter-
ations. Myocytes were organized in large and tortuous
strips, separated from each other by an important interstitial
fibrosis made up of the accumulation of collagen and elastic
fibers (Fig. 1, B and D). In these areas, myocytes were of
irregular shape and of large size (diameter: 21.2 6 0.3 vs.
11.5 6 0.2 mm, in diseased and control samples respectively;
p , 0.001). A number of these large myocytes showed
marked structural alterations, including 1) the depletion of
contractile materials limited to the vicinity of the nucleus or
frequently involving the entire cytosol and 2) the cytosol
depleted of myofibrillar structure was filled with glycogen
granules (Fig. 1, E and F). Figure 2 shows a confocal
microphotograph of tissue sections labeled with anti-a-
actinin antibodies. Whereas in control atria, myofibrils were
organized in a well-aligned and striated network, diseased
atria showed vast areas of myofibrillar disruption. However,
the remaining myofibrils maintained their striated organi-
zation and showed no contraction bands, which indicated
preservation of membrane integrity (Fig. 2).
In tissue section from fibrillating and dilated atria, 64.4 6
6.3% of total myocytes (n 5 11 patients) showed severe
myolysis, whereas only 12.2 6 5.8% of total myocytes (n 5
9 patients) consisted of these cells in myocardium from atria
in sinus rhythm. However, a high percentage of myocytes
with myolysis (42.3 6 10.1% of total myocytes, n 5 8
patients) was also found in samples obtained from the hearts
of patients with a low left ventricular ejection fraction
(LLVEF) in sinus rhythm (Fig. 3). Most of these patients
showed a dilated atria and/or increased pulmonary artery
pressure, suggesting a degree of hemodynamic overload of
their right atria (Table 1).
Nuclear alterations in myocytes with myolysis. In control
sections, the majority of the myocytes showed nuclei of
uniform size with an ovoid shape and an apparent regular
distribution of the heterochromatin (Fig. 4A). In sections of
diseased myocardium, most of the myocytes with myolysis
had markedly enlarged nuclei, with an evenly distributed
heterochromatin (Fig. 4B). However, occasional nuclei were
shrunken, with condensed and reorganized heterochromatin
(Fig. 4D), and more rarely, nuclei appeared fragmented
(Fig. 4C). To determine if some of these large nuclei might
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represent attempted mitosis, sections (n 5 4) were stained
with the antibody MIB-1 directed against the antigen
Ki-67, the expression of which is associated with the reentry
of cells into the division cycle (21). In both control and
diseased specimens, we failed to detect the expression of this
antigen.
In situ detection of DNA cleavage using the TUNEL
method showed that a high percentage of myocytes with
myolysis had nuclei TUNEL positive (45.2 6 5%, n 5 8),
whereas almost none of the myocytes without structural
alterations contained TUNEL-positive nuclei (Fig. 5A).
The vast majority of nuclei with weak TUNEL staining
were of large size with a uniform distribution of their
heterochromatin (counterstained with hematoxylin) (Fig.
5B).
However, occasional nuclei (4.2 6 0.8%, n 5 8) were
shrunken with a strong TUNEL staining, indicating that
more extensive DNA cleavage was associated with these
nuclear alterations (Fig. 5, C and D). The observation in
tissue sections of only rare cells with strong nuclear TUNEL
positivity was also consistent with the lack of clear typical
ladders of regular size DNA detected after gel electrophore-
sis (Fig. 6).
Activation of PCD in diseased atrial myocardium. The
lack of detection of DNA nucleosome ladders may be
insufficient to eliminate the activation of PCD, which is a
transient and fast process involving a limited number of
myocytes. Indeed, immunohistochemistry analysis of the
expression of CASP-3 revealed that the expression of this
protease was enhanced in diseased (n 5 5) compared with
control samples (n 5 6). This is illustrated in Figure 7,
which shows that in a section from the diseased atrium (Fig.
7, B to D), marked CASP-3 staining was observed predom-
inantly in myocardial areas characterized by a high percent-
age of myocytes with sarcomeric depletion. The CASP-3
Figure 1. Tissue sections from control (A, C, E) and dilated and fibrillating atria (B, D, F). Collagen and elastic fibers were stained with
Masson’s trichrome (A, B), orcein (C, D) and glycogen granules with PAS (E, F), respectively (arrow), and nuclei were counterstained
with hematoxylin. A to E, bar 5 40 mm; E and F, bar 5 20 mm.
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immunostaining exhibited a coarse-grained appearance, and
in some myocytes the deposits overlaid the nucleus. The
majority of the CASP-3-labeled myocytes showed hyper-
chromatic nuclei with features of shrinkage. A fine perinu-
clear weak staining was observed in myocytes from the
control atrium (Fig. 7A). In all protein samples studied by
immunoblotting, we detected the pro-form (p32) of the
CASP-3 without significant difference in its level of expres-
sion among the different specimens. Only in patients with
chronic AF or with LLVEF was the activated form (p17) of
the CASP-3 detected (Fig. 8A). It is conceivable that the
higher expression of CASP-3 detected in diseased samples
compared with the control could result from the addition of
both p32 and activated forms.
Further evidence that PCD is activated in diseased atrial
myocardium was provided by studying the expression of the
proapoptotic BAX and the antiapoptotic BCL-2 proteins.
The analysis of these two proteins by immunochemistry
(data not shown) and immunoblotting showed that both
were expressed in control and diseased myocardium (Fig.
8B). Whereas BAX expression was not significantly differ-
ent among the different samples studied, the expression of
BCL-2 was downregulated in patients with chronic AF or
LLVEF. Densitometric analysis confirmed that the ratio of
p26-BCL-2/BAX was decreased in patients in AF or with
LLVEF (1.42) compared with controls (2.15). Of note, in
addition to the classical p26-kDa band representing BCL-2,
we consistently detected a smaller band of approximately
23 kDa, which could indicate the presence of a cleaved form
of BCL-2.
DISCUSSION
The results of this study indicate that fibrillating and
hemodynamically overloaded atria contain a number of
myocytes undergoing apoptosis. We found profound cyto-
architectural and cellular alterations of the human right
atrial myocardium. These alterations predominated in bi-
opsy specimens from chronically fibrillating and dilated
atria, but they were also seen in atrial samples from the heart
in sinus rhythm with altered left ventricular function. In
both groups of patients, a number of myocytes with myolysis
had activated a cell suicide program resembling apoptosis.
Approximately 12% of myocytes in the control atria
showed marked sarcomeric depletion, compared with 60%
in specimens of fibrillating atria and 40% in hearts with
LLVEF. The cellular alterations observed here are more
severe that those found in previous studies. For instance,
Mary-Rabine et al. (6) found that ,5% of myocytes had
structural alterations in the majority of their adult right
Figure 2. Immunostaining of atrial sections with antibodies
against sarcomeric a-actinin observed by means of confocal mi-
croscopy showing disruption of the myofibrillar apparatus in
myocytes from diseased (B) but not from control (A) atria. Insets
show higher magnifications of the myofibrillar areas indicated by
arrows in A and B, respectively. Bar 5 5 mm.
Figure 3. Percentage of myocytes with myolysis in tissue sections
from fibrillating atria (n 5 11 patients), from heart in sinus rhythm
with a normal (EF . 45%, n 5 9 patients) or a low left ventricular
function (EF , 45%, n 5 8 patients). **p , 0.001.
1582 Aime´-Sempe´ et al. JACC Vol. 34, No. 5, 1999
Apoptosis in Diseased Human Right Atria November 1, 1999:1577–86
atrial biopsies and that this value exceeded 10% only in
markedly dilated and fibrillating atria. The discrepancy
between these two studies may reflect the fact that this
process predominates in the right atrial appendage, whereas
the anterior free wall was studied by Mary-Rabine et al. (6).
Indeed, in a goat model of pacing-induced AF, cellular
alterations similar to those observed in our study also
predominated in the right appendage (9). Furthermore, the
marked cellular remodeling observed in patients in sinus
rhythm with LLVEF could contribute to the high incidence
of AF observed during heart failure (22).
The mechanisms underlying the cellular alterations seen
in diseased atria are still poorly understood (8,9). The
resemblance between myolytic atrial cells and myocytes seen
during cardiac development or in less specialized myocardial
tissue had led to suggestions that such myocytes may have
undergone a dedifferentiation process. This is also suggested
by the reexpression of some fetal phenotypic features such as
smooth a-actin (8) and the transition from a- to b-myosin
heavy chain observed in the present study (data not shown,
23). The notion that myocytes with myolysis are in a
dedifferentiated state could explain why these cells contain a
Figure 4. Staining of nuclei with DAPI. (A) Section from control
atria. (B) Section from a fibrillating atria with number of myocytes
with myolysis showing large nuclei with a redistribution of their
heterochromatin. Examples of fragmented (C, arrow) and con-
densated (D, arrow) nuclei from two sections of diseased atria.
Bar 5 20 mm.
Figure 5. Staining of tissue sections with the TUNEL. (A) None
of the nuclei of normally structured myocytes from control tissue
section was stained with TUNEL. (B) A high percentage of the
nuclei of myocytes with myolysis showed a weak dUTP staining.
(C and D) Examples of strong dUTP staining of nuclei showing
morphological alterations. Bar 5 20 mm.
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large nucleus with a homogenous distribution of hetero-
chromatin resembling that of fetal/embryonic cardiac myo-
cytes. However, these myocytes did not express the nuclear
antigen Ki-67, indicating that they had not reentered the
cell cycle. The high percentage of nuclei with dUTP
(deoxyuridine triphosphate)-positive labeling but no nuclear
abnormalities indicates a degree of DNA breakage, which
could reflect some level of transcription or defective DNA
repair. In chicken myoblasts and in human lymphocytes, it
has been shown that dedifferentiation is associated with the
occurrence of DNA-strand breaks, a process that may
signify some underlying mobility of the genome and be
required to relax tightly packed chromatin for the transcrip-
tion of new genes (24,25).
Evidence of activation of PCD in atrial myocardium.
Although myocytes with myolysis may exhibit some features
of dedifferentiation, it remains to be determined whether
the cells are in a long-term viable state that eventually can be
reversible or they eventually die by activating PCD. The
possibility that some myolytic myocytes undergo apoptotic
death was raised by the observations of shrunken nuclei with
clumps of chromatin and strong TUNEL staining. Because
myocytes showing these nuclear and DNA alterations had
intact membranes (indicated by the persistence of striated
myofibrils and the lack of contraction bands), cellular
Figure 6. Electrophoresis patterns of DNA extracted from two
control atria (lanes 1, 2) one dilated atria in sinus rhythm (lane 3)
and two fibrillating atria (lanes 4, 5). No typical DNA ladders
were observed in all the samples studied.
Figure 7. Immunohistochemical detection of the protease CASP-3 in atrial myocardium. (A) Control adult atrium shows weak, diffuse,
fine-granular CASP-3 immunoreactions in most myocytes. Note, that only singular fibers showed more intense CASP-3 immunoreactivity
(arrow). (B to D) A number of myocytes from dilated and fibrillating atria heavily loaded with coarse-grained CASP-3 deposits (B,
arrows). Note that nuclei of the most affected cells demonstrate hyperchromasia (C and D). Bar 5 20 mm.
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necrosis can be eliminated from consideration. Moreover,
the activation and increased expression of CASP-3, a
molecule involved in the final executional step of PCD, in
diseased atria is also consistent with the notion that a
number of myocytes are undergoing an apoptotic death.
This biological process is regulated by proteins such as
members of the BCL-2 family, and whereas the expression
of the proapoptotic protein BAX was the same in all
specimens studied, we found that the expression level of the
antiapoptotic protein BCL-2 was reduced in specimens of
diseased atrial myocardium. BAX expression is also un-
changed in human ventricular myocardium during terminal
heart failure, while BCL-2 expression is increased (16). This
has been interpreted as evidence for compensatory mecha-
nisms during apoptosis associated with heart failure. Al-
though there is no clear explanation for these differences in
the expression of BCL-2 proteins between atrial and ven-
tricular myocardium, these results suggest that in the human
heart the ratio of BCL-2 and BAX may play a key role in
the balance between life and death (26,27). Recent studies
have shown that BCL-2 could be a substrate for proteases
such as CASP-3 (28), resulting in the cleavage of the
26-kDa protein to produce a 23-kDa band and removal of
the BH4 domain of the protein, a domain necessary for its
antiapoptotic function (26,29). The weak 23-kDa band
consistently detected in atrial myocardium samples could
correspond to the cleaved form of BCL-2. However, we
cannot rule out the possibility that this lower band repre-
sents the BCL-2b, isoform or another unrecognized tissue-
specific form of BCL-2 protein.
Cellular alterations characteristic of the final phase of
PCD, such as cytoplasm condensation or nuclear and DNA
fragmentation, were rarely detected in this study. One
possible explanation is that apoptosis involved a very limited
number of atrial myocytes that may rapidly be removed from
the myocardium. Indeed, the chronic course of atria diseases
is inconsistent with the notion that major cell loss plays an
important role in their pathogenesis. An alternative expla-
nation is that myocytes expressing a high level of activated
death effectors and reduced BCL-2 protein expression are
more susceptible to death signals. In this case, minor
additional noxious stimuli may be sufficient to trigger the
death of occasional vulnerable myocytes in random fashion.
This is somewhat reminiscent of neurodegenerative diseases
such as Alzheimer’s disease, wherein neurons showing
DNA alterations may not be undergoing apoptotic death
but are rather in a living state in which they are more
vulnerable to death stimuli (30).
Study limitations. In the goat model of chronic AF,
Ausma et al. (8) found no evidence of nuclear alterations
resembling an apoptotic process. Beside the difference in
species, the discrepancy between these two studies may be
explained by the relatively short period of AF in the goat
model (a few weeks vs. a few years in the present study),
which may be insufficient to activate an apoptotic process.
Moreover, most of the patients with chronic AF in the
present study had marked atrial dilation, suggesting chronic
hemodynamic overload of their atria, which may be an
important factor in triggering a PCD pathway. For instance,
abnormal levels of resting tension have been shown to
induce apoptosis of ventricular myocytes (31). This mech-
anism may be particularly important for myocytes of thin
atrial walls, in which even moderate hemodynamic overload
could induce substantial overstretching. This may also
explain why atrial samples from patients in sinus rhythm
with a LLVEF (which is often accompanied by a degree of
hemodynamic overload of the atria) also had marked histo-
logical abnormalities and apoptotic cells. Our results raise
questions as to the nature of the pathogenic stimuli, i.e.,
altered hemodynamic load or a high beating rate, that
trigger the cell suicide program in atrial myocardium.
Conclusion. Our observation that atrial myocytes with
myolysis can undergo apoptotic death implies that the
cellular remodeling that occurs in diseased atrial myocar-
dium may be partially irreversible. This could contribute to
Figure 8. Expression of CASP-3, BCL-2 and BAX protein. (A)
Whereas p32 isoform of CASP-3 was detected in all patients, the
p17 isoform was detected only in patients with AF (lanes 2 and 5)
and in some patients with LLVEF (lanes 3 and 4). (B) A lower
expression of BCL-2 was observed in patients with AF (lanes 2
and 5) and with LLVEF (lanes 3, 4 and 7) compared with control
patients (lanes 1 and 6) while BAX expression was unchanged. In
all samples analyzed, a 23-kDa band was detected with antibody
directed against BCL-2, the expression of which was enhanced in
patients with AF (lanes 2 and 5) or with LLVEF (lanes 3, 4 and
7) compared with control patients (lanes 1 and 6). Tubulin was
used as a control of equal loading and, except for patient in lane 2,
soluble tubulin was the predominant form.
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the difficulty of restoring sinus rhythm and to the self-
perpetuation of AF.
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